St. George’s Respiratory Questionnaire

Abstract

The St. George’s Respiratory Questionnaire (SGRQ) is a globally recognized, disease-specific psychometric instrument engineered to evaluate health-related quality of life (HRQoL) and functional impairment in patients diagnosed with chronic airflow limitation, most notably chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis. Developed in 1991 by Paul W. Jones and colleagues at St George’s Hospital Medical School, University of London, the SGRQ addresses the critical dissociation between physiological biomarkers of airway obstruction (such as forced expiratory volume in one second, FEV₁) and patients’ everyday lived experiences, emotional well-being, and functional capacity. Comprising 50 items partitioned across two principal parts and yielding 76 individual responses, the questionnaire evaluates three distinct psychometric domains: Symptoms (measuring the frequency, duration, and severity of respiratory distress), Activity (evaluating physical activities that induce or are restricted by dyspnea), and Impacts (capturing the broad psychosocial disruptions, panic, medication burden, and loss of perceived control provoked by chronic airway disease). The instrument employs a sophisticated empirical item-weighting methodology derived from Thurstonian scaling techniques, transforming responses into component scores and an aggregated Total score ranging from 0 (denoting zero functional impairment or optimal health status) to 100 (indicating maximal health impairment). Psychometric evaluations consistently confirm high internal consistency (Cronbach’s alpha α = 0.88–0.94 for the Total score; subscales α = 0.70–0.89), robust test-retest reliability (intraclass correlation coefficients ≥ 0.80), and an internationally validated Minimal Clinically Important Difference (MCID) established at 4.0 units. With proven cross-cultural validity in more than 80 standardized linguistic adaptations, the SGRQ serves as a gold-standard primary and secondary endpoint in international clinical trials, pulmonary rehabilitation assessment, and longitudinal epidemiological research.

Keywords

St. George’s Respiratory Questionnaire, SGRQ, chronic obstructive pulmonary disease, COPD, asthma, health-related quality of life, psychometrics, patient-reported outcome measures, dyspnea, functional impairment, Thurstonian weighting, clinical trials, pulmonary rehabilitation, minimal clinically important difference, respiratory health status

Authors

The St. George’s Respiratory Questionnaire was originally conceptualized, designed, and psychometrically validated by a multidisciplinary team of pulmonary medicine clinicians, epidemiologists, and psychometric researchers at the Division of Physiological Medicine, St George’s Hospital Medical School (now St George’s, University of London), London, United Kingdom:

• Paul W. Jones, PhD, FRCP: Emeritus Professor of Respiratory Medicine, Institute for Infection and Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK. Principal investigator who spearheaded the theoretical construct definition, empirical weighting methodology, and clinical trial integration of the SGRQ and its COPD-specific derivative, the SGRQ-C.
• Frances H. Quirk, PhD, CPsychol: Research Psychologist and Psychometrician, Division of Physiological Medicine, St George’s Hospital Medical School, London, UK. Contributed extensively to the psychometric item reduction, qualitative interviews, construct validity verification, and factor-analytic validation of the questionnaire domains.
• Colin M. Baveystock, MB, BS: Clinical Research Fellow, Division of Physiological Medicine, St George’s Hospital Medical School, London, UK. Oversaw the primary clinical sampling, pulmonary function testing, spirometric cross-correlations, and test-retest clinical protocols.
• Peter Littlejohns, MD, FRCP, FFPHM: Senior Lecturer in Public Health Medicine and Epidemiology, Department of Public Health Sciences, St George’s Hospital Medical School, London, UK. Provided methodological oversight regarding epidemiological survey design, population standardization, and health services research applications.

Purpose

The primary purpose of the St. George’s Respiratory Questionnaire is to provide a standardized, highly discriminative, and responsive patient-reported outcome measure (PROM) designed to capture the unique health status, daily life limitations, and psychological distress of patients suffering from chronic obstructive pulmonary disorders. Prior to the development of the SGRQ, clinical evaluations of respiratory pathology relied almost exclusively upon objective physiological markers, notably spirometry (FEV₁, forced vital capacity [FVC], and peak expiratory flow). However, extensive clinical research revealed that FEV₁ correlates poorly with subjective symptom perception, functional exercise capacity, affective distress, and social role limitation. The SGRQ was formulated precisely to bridge this clinical-pathological divide by quantifying the subjective health status and functional disability experienced by the individual.

In clinical trials, the SGRQ serves as an international regulatory endpoint for assessing the therapeutic efficacy of novel pharmacotherapies (such as long-acting muscarinic antagonists [LAMAs], long-acting beta-agonists [LABAs], inhaled corticosteroids [ICS], and biological agents targeting specific inflammatory pathways). Changes in SGRQ scores quantify whether a pharmacological intervention achieves clinical relevance beyond statistical significance, relying on its well-established Minimal Clinically Important Difference (MCID) of 4.0 units. A therapeutic reduction of 4 points or greater signifies a clinically perceptible improvement in patient daily function and symptom burden.

Beyond pharmacotherapy trials, the SGRQ is widely implemented in pulmonary rehabilitation programs, surgical intervention evaluations (such as lung volume reduction surgery and bronchoscopic lung volume reduction), and longitudinal health services research. In clinical practice, the tool provides multidisciplinary healthcare teams—comprising pulmonologists, respiratory physiotherapists, clinical psychologists, and occupational therapists—with an item-level and domain-level profile of patient vulnerability. This granular insight facilitates tailored physical reconditioning, targeted behavioral and cognitive interventions to address breathlessness-induced panic, and longitudinal monitoring of disease progression and exacerbation recovery.

Psychological Construct

The SGRQ measures the overarching psychological and behavioral construct of disease-specific Health-Related Quality of Life (HRQoL) in the context of chronic respiratory illness. In psychometric theory, HRQoL represents a multidimensional latent construct encompassing the subjective perception of physical, emotional, and social well-being as altered by an underlying medical condition and its medical management. The SGRQ operationalizes this latent construct across three correlated yet functionally distinct first-order domains:

1. The Symptoms Domain

The Symptoms component operationalizes the patient’s perceived frequency, chronicity, and episodic severity of respiratory distress over a defined recall period (conventionally the preceding 12 months, or 1 to 3 months in acute and clinical trial variants). This domain captures cardinal clinical manifestations of chronic airway disease, including productive cough, phlegm/sputum expectoration, wheezing, nocturnal breathlessness, and acute exacerbation events (referred to in the instrument as “chest attacks”). Psychometrically, this domain measures the baseline distress evoked by physical sensations. It captures not only symptom occurrence, but also the temporal pattern and unpredictability of attacks, which provoke anticipatory anxiety and hypervigilance regarding somatic respiratory cues.

2. The Activity Domain

The Activity component measures physical and functional restrictions directly attributable to dyspnea (breathlessness). This domain focuses on the physical behaviors of daily living, differentiating between sedentary baseline states and varying gradients of exertion. It examines activities of daily living (ADLs) such as getting washed, dressing, ambulating within the domestic environment, walking outdoors on level ground, ascending stairs, climbing inclines, and engaging in leisure or manual labor. From a behavioral psychometric standpoint, the Activity subscale measures physical functional limitation while reflecting the behavioral avoidance of physical exertion. In respiratory illness, breathlessness often instigates a fear-avoidance spiral: patients systematically disengage from physical activity to circumvent dyspnea, leading to skeletal muscle deconditioning, exercise intolerance, and escalating disability.

3. The Impacts Domain

The Impacts component constitutes the most psychologically complex dimension of the SGRQ, capturing the broader systemic, social, emotional, and existential consequences of airway disease. This dimension incorporates several critical psychological sub-facets:

• Perceived Loss of Control and Helplessness: Items evaluate feelings of powerlessness regarding disease management (e.g., feeling unable to control chest problems, pessimistic expectations of progressive physical decline).
• Affective Panic and Anxiety: Items measure panic, terror, and catastrophizing experienced when acute dyspnea occurs (e.g., experiencing terror or acute panic when unable to catch one’s breath).
• Social Stigma and Embarrassment: Items evaluate social evaluation fears and public embarrassment linked to audible coughing, wheezing, or public utilization of inhaler devices and oxygen therapy.
• Role and Interpersonal Disruption: Items gauge feelings of perceived burden on family and neighbors, domestic strain, and severe curtailment of leisure, recreation, shopping, and vocational engagement.
• Medication Burden and Helplessness: Items address perceived pharmacological futility, side-effect burden, and lifestyle interference induced by medication regimens.

Theoretical Framework

The development and architectural taxonomy of the St. George’s Respiratory Questionnaire are grounded in multidimensional conceptual frameworks of chronic disease, human disability, and health status assessment. Three foundational theoretical models underpin its construct validity:

The Wilson and Cleary Model of Health-Related Quality of Life

The conceptual framework of the SGRQ aligns closely with the classification model proposed by Wilson and Cleary (1995), which links physiological variables, symptom status, functional status, general health perceptions, and overall quality of life into a causal continuum. In the SGRQ:

• Physiological Factors (airway obstruction, ventilation-perfusion mismatch, gas trapping) trigger Symptom Status, measured by Part 1 (Symptoms: cough, sputum, wheeze, breathlessness).
• Symptom Status directly impedes Functional Status, captured by Part 2, Sections 2 and 6 (Activity: limitations in walking, bathing, stair climbing).
• Functional Limitations interact with individual psychological characteristics and environmental factors to produce disruptions in General Health Perceptions and Social Roles, evaluated by Part 2, Sections 3, 4, 5, and 7 (Impacts: panic, social withdrawal, loss of autonomy, invalidity).

The Biopsychosocial Model of Illness

Grounded in the Biopsychosocial Model formulated by George Engel, the SGRQ explicitly rejects biological reductionism. The questionnaire asserts that biological pathology (e.g., cellular airway remodeling or alveolar wall destruction) does not hold a linear relationship with patient suffering or personal handicap. Rather, psychological appraisal (such as catastrophic interpretations of dyspnea) and social contexts (interpersonal dependency, social support networks, public stigma) mediate how biological impairment translates into functional disability. By evaluating emotional distress, social disruption, and medication-related beliefs alongside physical symptoms, the SGRQ captures the broader lived experience of chronic illness.

Leventhal’s Common-Sense Model of Self-Regulation

The SGRQ incorporates principles from Leventhal’s Common-Sense Model of Self-Regulation, which posits that patients construct cognitive and emotional representations of their illness. These cognitive representations include illness identity (symptoms), timeline (expecting the condition never to improve), consequences (loss of employment, domestic dependence), and control/cure beliefs (believing medication does not help, feeling lacking in personal control). The Impacts domain of the SGRQ reflects these cognitive and emotional representations, demonstrating how negative cognitive representations exacerbate functional decline.

Validity

The psychometric validity of the St. George’s Respiratory Questionnaire has been extensively evaluated across diverse patient cohorts, clinical trial populations, and international linguistic adaptations.

Construct and Convergent Validity

Construct validity was established in the initial validation studies by Jones et al. (1991, 1992) and confirmed in subsequent global trials. Convergent validity is demonstrated through predictable, moderate-to-strong correlations with both physiological measures and related patient-reported questionnaires:

• Objective Exercise Tolerance: The SGRQ Activity and Total scores correlate significantly with the Six-Minute Walk Distance (6MWD), with Pearson and Spearman correlation coefficients typically ranging from r = -0.40 to -0.65 (p < 0.001). As functional exercise distance declines, SGRQ impairment scores systematically rise.
• Dyspnea Severity Scales: Strong convergent correlations exist between SGRQ scores and dyspnea indices, including the Medical Research Council (MRC) / modified MRC (mMRC) dyspnea scale (r = 0.55 to 0.72) and the Baseline Dyspnea Index (BDI) / Transition Dyspnea Index (TDI).
• Generic HRQoL Measures: SGRQ domain scores correlate systematically with conceptually congruent domains of generic instruments, such as the Short Form Health Survey (SF-36). The SGRQ Activity domain correlates strongly with the SF-36 Physical Functioning scale (r = -0.60 to -0.75), whereas the SGRQ Impacts domain correlates with the SF-36 Role Emotional and Mental Health subscales (r = -0.45 to -0.60).
• Physiological Airway Obstruction: Correlations between SGRQ Total scores and spirometric airflow obstruction (FEV₁ percentage of predicted) are consistently modest (typically r = -0.25 to -0.40). This modest association is clinically expected, reinforcing that the SGRQ captures a distinct domain of health status that cannot be inferred from spirometry alone.

Discriminant and Known-Groups Validity

The SGRQ demonstrates discriminant validity across differing stages of disease severity as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD Stages 1 through 4). Total and subscale SGRQ scores show statistically significant stepwise elevations across increasing GOLD stages (p < 0.001). Furthermore, the instrument discriminates effectively between patients with frequent exacerbations (≥ 2 exacerbations per year) and non-frequent exacerbators, with frequent exacerbators demonstrating Total scores 8 to 14 points worse on average.

Predictive Validity

Extensive prospective longitudinal studies have confirmed the predictive validity of the SGRQ for adverse clinical outcomes:

• Mortality: Baseline SGRQ Total score is an independent predictor of all-cause and respiratory mortality in patients with COPD, even after adjusting for age, smoking status, body mass index, comorbidity index, and FEV₁. Each 4-point elevation (worsening) in baseline SGRQ score is associated with an approximate 6% to 11% increase in prospective mortality hazard.
• Hospitalization and Exacerbations: Poorer baseline SGRQ scores predict higher rates of future emergency department visits, severe exacerbation-related hospitalizations, and prolonged length of hospital stay.

Responsiveness and Minimal Clinically Important Difference (MCID)

The SGRQ is sensitive to therapeutic change. In rehabilitation trials, surgical interventions, and pharmacological randomized controlled trials, the instrument detects both symptomatic improvements and disease deterioration. Through combined anchor-based and distribution-based psychometric techniques, the Minimal Clinically Important Difference was established as a change of 4.0 units. A decrement of ≥ 4.0 points represents a clinically meaningful improvement, whereas an increase of ≥ 4.0 points indicates a clinically perceptible deterioration in health status.

Reliability

The St. George’s Respiratory Questionnaire demonstrates strong reliability across diverse clinical populations, languages, and testing environments.

Internal Consistency

Internal consistency has been thoroughly documented across clinical investigations. Cronbach’s alpha (α) coefficients routinely exceed established psychometric thresholds for group comparisons (α ≥ 0.70) and individual monitoring (α ≥ 0.90):

• Total Score: Cronbach’s α typically ranges between 0.92 and 0.95, indicating excellent overall reliability.
• Symptoms Subscale: Cronbach’s α typically ranges from 0.72 to 0.82. The comparatively lower coefficient in this domain reflects the multidimensional nature of respiratory symptoms (e.g., the physiological divergence between acute bronchospastic wheeze and chronic phlegm expectoration).
• Activity Subscale: Cronbach’s α ranges from 0.88 to 0.93, reflecting high homogeneity among items assessing physical exertion limitations.
• Impacts Subscale: Cronbach’s α ranges from 0.87 to 0.91, indicating cohesive measurement of the psychosocial, emotional, and everyday disruptions caused by chronic lung disease.

Test-Retest Reliability and Stability

In clinically stable outpatients assessed at intervals ranging from 2 weeks to 4 weeks (in the absence of acute exacerbations or treatment alterations), the SGRQ exhibits high reproducibility:

• Intraclass Correlation Coefficients (ICC): Test-retest ICCs for the Total score range from 0.84 to 0.92. Component subscales demonstrate similarly strong coefficients: Symptoms (ICC = 0.78–0.86), Activity (ICC = 0.86–0.91), and Impacts (ICC = 0.82–0.90).
• Repeatability Coefficients: Repeated testing under stable conditions indicates that random measurement error remains within 3 to 5 scale units, corroborating that a 4-point change reflects true therapeutic alteration rather than test-retest measurement noise.

Factor Analysis

The structural dimensionality of the SGRQ has been investigated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA), alongside Item Response Theory (IRT) and Rasch measurement models.

Original Factor Structure and Scaling

In the seminal psychometric work by Jones et al. (1991), candidate items were developed from qualitative clinical interviews with patients suffering from severe airflow limitation. Factor analytic evaluations using principal component analysis with orthogonal (Varimax) and oblique rotations consistently yielded a three-factor solution explaining between 45% and 55% of the total variance across the item pool:

• Factor 1 (Activity): Highly defined by items measuring mobility, self-care speed, and physical exertion (e.g., walking up hills, walking up stairs, household chores), with factor loadings consistently exceeding 0.55 to 0.80.
• Factor 2 (Impacts): Defined by items measuring emotional panic, lifestyle control, social embarrassment, invalidity, and disturbance of domestic routines, displaying primary factor loadings between 0.45 and 0.75.
• Factor 3 (Symptoms): Dominated by items measuring the frequency, duration, and episodic severity of wheezing, cough, breathlessness, and acute exacerbations, with factor loadings ranging from 0.40 to 0.78.

Confirmatory Factor Analysis (CFA) and Goodness-of-Fit

Subsequent contemporary structural equation modeling studies evaluating the three-factor hierarchical model across international cohorts have demonstrated adequate model fit:

• Goodness-of-Fit Indices: CFA evaluations often report Comparative Fit Index (CFI) values ranging between 0.90 and 0.94, Tucker-Lewis Index (TLI) values between 0.89 and 0.93, and Root Mean Square Error of Approximation (RMSEA) values between 0.045 and 0.062 (90% CI [0.041, 0.066]), indicating reasonable model fit for a complex 50-item multidimensional scale.
• Higher-Order General Factor: CFAs support a second-order general factor representing overall “Respiratory Health Status” or “Respiratory-Related Functional Impairment”, which accounts for the substantial inter-factor correlations observed among Symptoms, Activity, and Impacts (latent correlations r = 0.50 to 0.72).

Rasch Analysis and the Development of the SGRQ-C

Application of Rasch measurement modeling and Item Response Theory (IRT) to the SGRQ by Meguro et al. (2007) and Jones (2012) identified minor psychometric anomalies within the original instrument, particularly when applied strictly to COPD populations. Several items in the Symptoms domain (such as items addressing wheezing worse in the morning or seasonal recall) displayed differential item functioning (DIF) or poor fit statistics. This work led to the development of the SGRQ-C (COPD-Specific Version), a 40-item derivation in which 10 psychometrically weaker or asthma-specific items were removed, and the recall period was standardized, achieving improved unidimensional fit within individual domains while preserving structural equivalence to the original instrument.

Instrument / Measurement Tool

The standard SGRQ is structured as follows:

• Test Type: Disease-specific Patient-Reported Outcome Measure (PROM) / Health-Related Quality of Life (HRQoL) questionnaire.
• Administration Format: Self-administered paper-and-pencil or validated electronic PROM (eCOA/ePRO) via computer, tablet, or handheld device. Can be administered by a trained interviewer if the respondent has literacy or visual impairments.
• Target Population: Adult and elderly patients (aged 18 years and older) diagnosed with chronic airflow limitation, primarily COPD, asthma, bronchiectasis, or interstitial lung disease.
• Item Count: 50 items yielding 76 distinct response items/weights across two parts: Part 1 contains 8 numbered items with multi-category response options; Part 2 contains 42 numbered items partitioned across 7 sections, utilizing dichotomous responses and a 4-point rating scale.
• Response Formats:
  • Part 1: Multiple-choice frequency options (e.g., “Most days a week”, “Several days a week”, “A few days a month”, “Only with chest infections”, “Not at all”) and categorical duration/severity ratings.
  • Part 2: Dichotomous (True / False) responses across individual activity, symptom-consequence, and lifestyle statements; and a 4-point categorical scale (Questions 9–12) for overall chest condition.
• Completion Time: Approximately 10 to 15 minutes for self-administration.
• Scoring System and Mathematical Algorithm:
  • The SGRQ does not use simple ordinal summations. Instead, it utilizes an empirically weighted scoring algorithm derived from pairwise comparison scaling (Thurstonian weights).
  • Each individual response option is assigned a unique, empirically validated empirical weight (ranging from zero to roughly 90+ units).
  • Four scores are computed:
    1. Symptoms Score: Derived from Part 1 items. Measures the frequency and distress of respiratory symptoms.
    2. Activity Score: Derived from Part 2 (Section 2 and Section 6). Measures physical activities that cause breathlessness or are restricted by it.
    3. Impacts Score: Derived from Part 2 (Section 1, Section 3, Section 4, Section 5, and Section 7). Measures psychosocial disruption, affective disturbance, panic, medication burden, and dependency.
    4. Total Score: Aggregated summary score synthesizing all completed domains.
  • Score Calculation Formula: For each domain and the Total score, the score is calculated by dividing the sum of the weights of all positive responses by the maximum possible sum of weights for that domain, multiplied by 100:
    
    Score = 100 × (∑ weights of positive responses) / (∑ maximum possible weights for answered items)
  • Scale Range: All scores range from 0 (optimal health status, no functional impairment or symptom distress) to 100 (worst possible health status, maximum functional limitation).
  • Missing Data Rules: Official scoring guidelines permit calculation if missing items remain within prescribed thresholds: missing items in Symptoms must not exceed 2; in Activity, no more than 4; in Impacts, no more than 6. If missing items exceed these thresholds, the respective component score cannot be reliably calculated.

Permissions & Fee and Test Year

The St. George’s Respiratory Questionnaire was originally published in 1991 (with extensive validation published in 1992) by Professor Paul W. Jones at St George’s Hospital Medical School, University of London. The COPD-specific shortened variant, the SGRQ-C, was published in 2012.

Copyright and Licensing: The SGRQ, SGRQ-C, and their official translations are protected under international copyright owned by St George’s, University of London. Commercial pharmaceutical clinical trials, contract research organizations (CROs), and funded commercial entities must obtain a formal user license and pay associated licensing and distribution fees. Academic researchers, non-funded clinical investigators, and routine clinical healthcare services may typically access the questionnaire and scoring software under royalty-free or discounted academic licenses, subject to formal registration and approval.

Distribution and Access: Licensing, official linguistic validations, and scoring spreadsheets are managed and distributed via the Mapi Research Trust / ePROVIDE platform. Users must register their study protocol, sign a user agreement, and utilize verified translations to ensure data integrity and prevent copyright infringement.

References

• Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991). The St George’s Respiratory Questionnaire. Respiratory Medicine, 85(Suppl B), 25–31. https://doi.org/10.1016/s0954-6111(06)80166-6
• Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992). A self-complete measure of health status for chronic airflow limitation: The St. George’s Respiratory Questionnaire. American Review of Respiratory Disease, 145(6), 1321–1327. https://doi.org/10.1164/ajrccm/145.6.1321
• Jones, P. W. (2002). Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal, 19(3), 398–404. https://doi.org/10.1183/09031936.02.00039802
• Jones, P. W. (2005). St. George’s Respiratory Questionnaire: MCID. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2(1), 75–79. https://doi.org/10.1081/copd-200050513
• Meguro, M., Barley, E. A., Spencer, S., & Jones, P. W. (2007). Development and validation of an updated COPD-specific version of the St. George’s Respiratory Questionnaire: SGRQ-C. Chest, 132(2), 456–463. https://doi.org/10.1378/chest.06-0702
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250067039
• Kon, S. S., Canavan, J. L., Jones, S. E., Nolan, C. M., Clark, A. L., Dickson, M. J., Haselton, T. E., Polkey, M. I., & Man, W. D. (2014). Minimum clinically important difference for the COPD Assessment Test: A prospective analysis. The Lancet Respiratory Medicine, 2(3), 195–203. https://doi.org/10.1016/S2213-2600(14)70001-3
• Vestbo, J., Hurd, S. S., Agustí, A. G., Sanchez-Saldaña, M., Jones, P. W., Vogelmeier, C., Lopez Varela, M. V., Hallstrom, A., Rodriguez-Roisin, R., Stockley, R. A., & Wedzicha, J. A. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine, 187(4), 347–365. https://doi.org/10.1164/rccm.201204-0596PP

13. Items of the Scale (Questionnaire)